Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Biomea Fusion, Inc.BMEA · Entity 6606 | Chief Financial Officer | November 30, 2024 | December 02, 2024 |
| IOVANCE BIOTHERAPEUTICS, INC.LBIO · Entity 2090 | Principal Accounting Officer | August 22, 2016 | April 03, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Biomea Fusion, Inc.
Report date November 30, 2024 · Filed December 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 42,995 |
Reported balance
After 2024-11-30 transaction · row 1
1 source rowRow 1 · 2024-11-30 · Grant · Acquired 495 · Balance 42,995 F1: These shares were acquired under the Biomea Fusion, Inc. 2021 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). F2: In accordance with the ESPP, these shares were purchased at a purchase price of 85% of the fair market value of the Issuer's common stock on November 29, 2024. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were acquired under the Biomea Fusion, Inc. 2021 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).
F2: In accordance with the ESPP, these shares were purchased at a purchase price of 85% of the fair market value of the Issuer's common stock on November 29, 2024.
IOVANCE BIOTHERAPEUTICS, INC.
Report date August 22, 2016 · Filed April 03, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 130 |
Reported balance
Holding disclosure · report date 2016-08-22 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 130 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.10 · Expires 2026-08-16 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2016-08-22 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: The option will vest as to 28,333 shares on July 25, 2017 and the remaining 56,667 shares will vest quarterly over the next two years after July 25, 2017, provided the Reporting Person is still providing services to the Issuer on the respective dates. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.45 · Expires 2027-03-16 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2016-08-22 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F2: The option will vest as to 2,067 shares on February 1, 2018 and the remaining 4,133 shares will vest quarterly over the next two years after February 1, 2018, provided the Reporting Person is still providing services to the Issuer on the respective dates. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest as to 28,333 shares on July 25, 2017 and the remaining 56,667 shares will vest quarterly over the next two years after July 25, 2017, provided the Reporting Person is still providing services to the Issuer on the respective dates.
F2: The option will vest as to 2,067 shares on February 1, 2018 and the remaining 4,133 shares will vest quarterly over the next two years after February 1, 2018, provided the Reporting Person is still providing services to the Issuer on the respective dates.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Eidos Therapeutics, Inc.
Report date January 26, 2021 · Filed January 28, 2021
Section 16 reporting ended · disclosed 2021-01-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.24 · Expires 2028-05-06 | Direct | 0 |
Reported balance
After 2021-01-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-01-26 · Disposition to issuer · Disposed 24,350 · Balance 0 F1: Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among the Issuer, BridgeBio Pharma, Inc. ("Parent"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub II"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time"). F2: (Continued From Footnote 1) The option vests over four years after March 28, 2018. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among the Issuer, BridgeBio Pharma, Inc. ("Parent"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub II"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time").
F2: (Continued From Footnote 1) The option vests over four years after March 28, 2018. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 30, 2024 Filed Dec 2, 2024 16:30 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | GrantCommon Stock | 495 | $6.15 | $3,046.23 |
DisclosureSEC source: 0000950170-24-132253 · ownership.xml · nonDerivative · entry 1 Valle Franco · CIK 0001699848 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,995 F1 · kind: These shares were acquired under the Biomea Fusion, Inc. 2021 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased at a purchase price of 85% of the fair market value of the Issuer's common stock on November 29, 2024. Read SEC document |
| June 11, 2024 Filed Jun 12, 2024 16:30 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | PurchaseCommon Stock | 12,509 | $4.43 | $55,361.08 |
DisclosureSEC source: 0000950170-24-072494 · ownership.xml · nonDerivative · entry 2 Valle Franco · CIK 0001699848 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,500 F3 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.4199 to $4.4299, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| May 31, 2024 Filed Jun 12, 2024 16:30 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | GrantCommon Stock | 4,448 | $3.78 | $16,824.56 |
DisclosureSEC source: 0000950170-24-072494 · ownership.xml · nonDerivative · entry 1 Valle Franco · CIK 0001699848 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,991 F1 · kind: These shares were acquired under the Biomea Fusion, Inc. 2021 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased at a purchase price of 85% of the fair market value of the Issuer's common stock on June 1, 2022. Read SEC document |
| January 17, 2024 Filed Jan 18, 2024 16:30 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | GrantStock Option (Right to Buy) · Derivative | 145,245 | $0.00 Strike: $14.44 | $0.00 |
DisclosureSEC source: 0000950170-24-005416 · ownership.xml · derivative · entry 1 Valle Franco · CIK 0001699848 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 145,245 Underlying: Common Stock · 145,245 shares Expires 2034-01-16 F1 · derivative.exercise_date: The option shall vest and become exercisable in quarterly installments over four years, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| November 30, 2023 Filed Dec 1, 2023 17:58 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | GrantCommon Stock | 1,345 | $3.78 | $5,087.46 |
DisclosureSEC source: 0000950170-23-067424 · ownership.xml · nonDerivative · entry 1 Valle Franco · CIK 0001699848 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,543 F1 · kind: These shares were acquired under the Biomea Fusion, Inc. 2021 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased at a purchase price of 85% of the fair market value of the Issuer's common stock on June 1, 2022. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 17:01 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | GrantCommon Stock | 4,273 | $3.78 | $16,162.62 |
DisclosureSEC source: 0000950170-23-026142 · ownership.xml · nonDerivative · entry 1 Valle Franco · CIK 0001699848 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,198 F1 · kind: These shares were acquired under the Biomea Fusion, Inc. 2021 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased at a purchase price of 85% of the fair market value of the Issuer's common stock on June 1, 2022. Read SEC document |
| January 06, 2023 Filed Jan 10, 2023 17:00 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | GrantStock Option (Right to Buy) · Derivative | 126,300 | $0.00 Strike: $7.05 | $0.00 |
DisclosureSEC source: 0000899243-23-001486 · doc4.xml · derivative · entry 1 Valle Franco · CIK 0001699848 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,300 Underlying: Common Stock · 126,300 shares Expires 2033-01-05 F1 · derivative.exercise_date: The option shall vest and become exercisable in quarterly installments over four years, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| November 30, 2022 Filed Dec 2, 2022 16:30 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | GrantCommon Stock | 2,518 | $3.78 | $9,524.34 |
DisclosureSEC source: 0000899243-22-037438 · doc4.xml · nonDerivative · entry 1 Valle Franco · CIK 0001699848 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,925 F1 · kind: These shares were acquired under the Biomea Fusion, Inc. 2021 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased at a purchase price of 85% of the fair market value of the Issuer's common stock on June 1, 2022. Read SEC document |
| November 11, 2022 Filed Nov 14, 2022 16:30 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | PurchaseCommon Stock | 4,100 | $7.63 | $31,285.87 |
DisclosureSEC source: 0000899243-22-035697 · doc4.xml · nonDerivative · entry 1 Valle Franco · CIK 0001699848 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,407 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $7.6000 to $7.6499, inclusive. The reporting person undertakes to provide to Biomea Fusion, Inc., any security holder of Biomea Fusion, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote 1 to this Form 4. Read SEC document |
| May 31, 2022 Filed Jun 1, 2022 18:00 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | GrantCommon Stock | 3,307 | $4.67 | $15,432.12 |
DisclosureSEC source: 0000899243-22-020517 · doc4.xml · nonDerivative · entry 1 Valle Franco · CIK 0001699848 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,307 F1 · kind: These shares were acquired under the Biomea Fusion, Inc. 2021 Employee Stock Purchase Plan ("ESPP") in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased at a purchase price of 85% of the closing price of the Issuer's common stock on May 31, 2022. Read SEC document |
| January 14, 2022 Filed Jan 18, 2022 19:00 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | PurchaseCommon Stock | 10,000 | $8.68 | $86,767.00 |
DisclosureSEC source: 0000899243-22-002217 · doc4.xml · nonDerivative · entry 1 Valle Franco · CIK 0001699848 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 F1 · price: The price reported in Column 4 is a weighted-average price. These shares were purchased in multiple transactions at prices ranging from $8.5550 to $8.7400, inclusive. The reporting person undertakes to provide to Biomea Fusion, Inc., any security holder of Biomea Fusion, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote 1 to this Form 4. Read SEC document |
| December 04, 2021 Filed Dec 7, 2021 17:25 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | GrantStock Option (Right to Buy) · Derivative | 144,770 | $0.00 Strike: $9.80 | $0.00 |
DisclosureSEC source: 0001567619-21-021720 · doc1.xml · derivative · entry 1 Valle Franco · CIK 0001699848 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,770 Underlying: Common Stock · 144,770 shares Expires 2031-12-03 F1 · derivative.exercise_date: The option shall vest and become exercisable in quarterly installments over four years, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| August 03, 2021 Filed Aug 5, 2021 19:25 UTC | Biomea Fusion, Inc. BMEA · Entity 6606 | GrantStock Option (Right to Buy) · Derivative | 165,000 | $0.00 Strike: $13.45 | $0.00 |
DisclosureSEC source: 0001567619-21-014561 · doc1.xml · derivative · entry 1 Valle Franco · CIK 0001699848 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 165,000 Underlying: Common Stock · 165,000 shares Expires 2031-07-25 F1 · derivative.exercise_date: The option shall vest and become exercisable in quarterly installments over four years, subject to the Reporting Person's continued service to the Issuer though each vesting date. Read SEC document |
| January 26, 2021 Filed Jan 28, 2021 19:22 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Disposition to issuerStock Option (Right to Buy) · Derivative | 24,350 | Not disclosed Strike: $7.24 | Not disclosed |
DisclosureSEC source: 0000899243-21-003651 · doc4.xml · derivative · entry 1 Valle Franco · CIK 0001699848 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,350 shares Expires 2028-05-06 F1 · price: Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among the Issuer, BridgeBio Pharma, Inc. ("Parent"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub II"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time"). F2 · price: (Continued From Footnote 1) The option vests over four years after March 28, 2018. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time. F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among the Issuer, BridgeBio Pharma, Inc. ("Parent"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub II"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time"). F2 · derivative.exercise_date: (Continued From Footnote 1) The option vests over four years after March 28, 2018. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time. Read SEC document |
| January 12, 2021 Filed Jan 13, 2021 16:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,747 | $0.00 Strike: $7.24 | $0.00 |
DisclosureSEC source: 0000899243-21-001847 · doc4.xml · derivative · entry 6 Valle Franco · CIK 0001699848 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,350 Underlying: Common Stock · 1,747 shares Expires 2028-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option, originally representing a right to purchase a total of 77,919 shares, vested and became exercisable as to 25% of the original option on March 28, 2019, and the remainder vests in 36 additional monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| January 12, 2021 Filed Jan 13, 2021 16:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 1,747 | $125.45 | $219,152.42 |
DisclosureSEC source: 0000899243-21-001847 · doc4.xml · nonDerivative · entry 4 Valle Franco · CIK 0001699848 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| January 12, 2021 Filed Jan 13, 2021 16:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionCommon Stock | 1,747 | $7.24 | $12,648.28 |
DisclosureSEC source: 0000899243-21-001847 · doc4.xml · nonDerivative · entry 3 Valle Franco · CIK 0001699848 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,747 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 16:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,500 | $0.00 Strike: $7.24 | $0.00 |
DisclosureSEC source: 0000899243-21-001847 · doc4.xml · derivative · entry 5 Valle Franco · CIK 0001699848 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,097 Underlying: Common Stock · 1,500 shares Expires 2028-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option, originally representing a right to purchase a total of 77,919 shares, vested and became exercisable as to 25% of the original option on March 28, 2019, and the remainder vests in 36 additional monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 16:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 1,500 | $125.61 | $188,407.50 |
DisclosureSEC source: 0000899243-21-001847 · doc4.xml · nonDerivative · entry 2 Valle Franco · CIK 0001699848 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 16:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionCommon Stock | 1,500 | $7.24 | $10,860.00 |
DisclosureSEC source: 0000899243-21-001847 · doc4.xml · nonDerivative · entry 1 Valle Franco · CIK 0001699848 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 16:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,623 | $0.00 Strike: $7.24 | $0.00 |
DisclosureSEC source: 0000899243-20-030728 · doc4.xml · derivative · entry 3 Valle Franco · CIK 0001699848 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,597 Underlying: Common Stock · 1,623 shares Expires 2028-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option, originally representing a right to purchase a total of 77,919 shares, vested and became exercisable as to 25% of the original option on March 28, 2019, and the remainder vests in 36 additional monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 16:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 1,623 | $74.93 | $121,609.28 |
DisclosureSEC source: 0000899243-20-030728 · doc4.xml · nonDerivative · entry 2 Valle Franco · CIK 0001699848 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Represents the weighted average sale price of the shares sold from $74.82 to $75.12 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 09, 2020 Filed Nov 10, 2020 16:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionCommon Stock | 1,623 | $7.24 | $11,750.52 |
DisclosureSEC source: 0000899243-20-030728 · doc4.xml · nonDerivative · entry 1 Valle Franco · CIK 0001699848 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 08, 2020 Filed Oct 9, 2020 17:23 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,199 | $0.00 Strike: $7.24 | $0.00 |
DisclosureSEC source: 0000899243-20-027918 · doc4.xml · derivative · entry 6 Valle Franco · CIK 0001699848 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,220 Underlying: Common Stock · 5,199 shares Expires 2028-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, originally representing a right to purchase a total of 77,919 shares, vested and became exercisable as to 25% of the original option on March 28, 2019, and the remainder vests in 36 additional monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| October 08, 2020 Filed Oct 9, 2020 17:23 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 5,199 | $74.85 | $389,150.87 |
DisclosureSEC source: 0000899243-20-027918 · doc4.xml · nonDerivative · entry 4 Valle Franco · CIK 0001699848 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: Represents the weighted average sale price of the shares sold from $74.77 to $74.95 per share. Read SEC document |
| October 08, 2020 Filed Oct 9, 2020 17:23 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionCommon Stock | 5,199 | $7.24 | $37,640.76 |
DisclosureSEC source: 0000899243-20-027918 · doc4.xml · nonDerivative · entry 3 Valle Franco · CIK 0001699848 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 07, 2020 Filed Oct 9, 2020 17:23 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $7.24 | $0.00 |
DisclosureSEC source: 0000899243-20-027918 · doc4.xml · derivative · entry 5 Valle Franco · CIK 0001699848 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,419 Underlying: Common Stock · 5,000 shares Expires 2028-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, originally representing a right to purchase a total of 77,919 shares, vested and became exercisable as to 25% of the original option on March 28, 2019, and the remainder vests in 36 additional monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| October 07, 2020 Filed Oct 9, 2020 17:23 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 5,444 | $75.08 | $408,748.04 |
DisclosureSEC source: 0000899243-20-027918 · doc4.xml · nonDerivative · entry 2 Valle Franco · CIK 0001699848 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Represents the weighted average sale price of the shares sold from $74.9701 to $75.3901 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 1 and 2. Read SEC document |
| October 07, 2020 Filed Oct 9, 2020 17:23 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionCommon Stock | 5,000 | $7.24 | $36,200.00 |
DisclosureSEC source: 0000899243-20-027918 · doc4.xml · nonDerivative · entry 1 Valle Franco · CIK 0001699848 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,444 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 31, 2020 Filed Jun 5, 2020 16:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | GrantCommon Stock | 444 | $41.57 | $18,458.63 |
DisclosureSEC source: 0000899243-20-015411 · doc4.xml · nonDerivative · entry 1 Valle Franco · CIK 0001699848 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 444 F1 · kind: Shares acquired pursuant to the Issuer's 2018 Employee Stock Purchase Plan. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 16:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionStock Option (right to buy) · Derivative | 2,000 | $0.00 Strike: $7.24 | $0.00 |
DisclosureSEC source: 0000899243-20-011154 · doc4.xml · derivative · entry 3 Valle Franco · CIK 0001699848 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,419 Underlying: Common Stock · 2,000 shares Expires 2028-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option, originally representing a right to purchase a total of 77,919 shares, vested and became exercisable as to 25% of the original option on March 28, 2019, and the remainder vests in 36 additional monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 16:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 2,000 | $49.79 | $99,580.00 |
DisclosureSEC source: 0000899243-20-011154 · doc4.xml · nonDerivative · entry 2 Valle Franco · CIK 0001699848 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Represents the weighted average sale price of the shares sold from $49.69 to $49.84 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| April 20, 2020 Filed Apr 22, 2020 16:05 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionCommon Stock | 2,000 | $7.24 | $14,480.00 |
DisclosureSEC source: 0000899243-20-011154 · doc4.xml · nonDerivative · entry 1 Valle Franco · CIK 0001699848 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 26, 2020 Filed Mar 30, 2020 16:23 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $7.24 | $0.00 |
DisclosureSEC source: 0000899243-20-009640 · doc4.xml · derivative · entry 4 Valle Franco · CIK 0001699848 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,419 Underlying: Common Stock · 5,000 shares Expires 2028-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option, originally representing a right to purchase a total of 77,919 shares, vested and became exercisable as to 25% of the original option on March 28, 2019, and the remainder vests in 36 additional monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| March 26, 2020 Filed Mar 30, 2020 16:23 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 2,000 | $48.85 | $97,700.00 |
DisclosureSEC source: 0000899243-20-009640 · doc4.xml · nonDerivative · entry 3 Valle Franco · CIK 0001699848 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F2 · price: Represents the weighted average sale price of the shares sold from $48.71 to $49.00 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 26, 2020 Filed Mar 30, 2020 16:23 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 3,000 | $47.87 | $143,610.00 |
DisclosureSEC source: 0000899243-20-009640 · doc4.xml · nonDerivative · entry 2 Valle Franco · CIK 0001699848 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 F1 · price: Represents the weighted average sale price of the shares sold from $47.37 to $48.13 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 26, 2020 Filed Mar 30, 2020 16:23 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionCommon Stock | 5,000 | $7.24 | $36,200.00 |
DisclosureSEC source: 0000899243-20-009640 · doc4.xml · nonDerivative · entry 1 Valle Franco · CIK 0001699848 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 16:08 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionStock Option (right to buy) · Derivative | 3,000 | $0.00 Strike: $7.24 | $0.00 |
DisclosureSEC source: 0000899243-20-006944 · doc4.xml · derivative · entry 4 Valle Franco · CIK 0001699848 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,419 Underlying: Common Stock · 3,000 shares Expires 2028-05-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option, originally representing a right to purchase a total of 77,919 shares, vested and became exercisable as to 25% of the original option on March 28, 2019, and the remainder vests in 36 additional monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 16:08 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 1,000 | $53.06 | $53,060.00 |
DisclosureSEC source: 0000899243-20-006944 · doc4.xml · nonDerivative · entry 3 Valle Franco · CIK 0001699848 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 16:08 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | SaleCommon Stock | 2,000 | $51.96 | $103,920.00 |
DisclosureSEC source: 0000899243-20-006944 · doc4.xml · nonDerivative · entry 2 Valle Franco · CIK 0001699848 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 F1 · price: Represents the weighted average sale price of the shares sold from $51.92 to $52.01 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 02, 2020 Filed Mar 4, 2020 16:08 UTC | Eidos Therapeutics, Inc. EIDX · Entity 143355 | Exercise / conversionCommon Stock | 3,000 | $7.24 | $21,720.00 |
DisclosureSEC source: 0000899243-20-006944 · doc4.xml · nonDerivative · entry 1 Valle Franco · CIK 0001699848 · Senior Vice President, Finance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.